JP2018531937A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531937A5
JP2018531937A5 JP2018517270A JP2018517270A JP2018531937A5 JP 2018531937 A5 JP2018531937 A5 JP 2018531937A5 JP 2018517270 A JP2018517270 A JP 2018517270A JP 2018517270 A JP2018517270 A JP 2018517270A JP 2018531937 A5 JP2018531937 A5 JP 2018531937A5
Authority
JP
Japan
Prior art keywords
composition
subject
mutation
treatment
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018517270A
Other languages
English (en)
Japanese (ja)
Other versions
JP6940853B2 (ja
JP2018531937A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/054457 external-priority patent/WO2017059076A1/en
Publication of JP2018531937A publication Critical patent/JP2018531937A/ja
Publication of JP2018531937A5 publication Critical patent/JP2018531937A5/ja
Priority to JP2021064764A priority Critical patent/JP7752373B2/ja
Application granted granted Critical
Publication of JP6940853B2 publication Critical patent/JP6940853B2/ja
Priority to JP2022155051A priority patent/JP2022173426A/ja
Priority to JP2024204921A priority patent/JP2025019234A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018517270A 2015-09-30 2016-09-29 メラノコルチン４受容体経路関連障害を治療する方法 Active JP6940853B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021064764A JP7752373B2 (ja) 2015-09-30 2021-04-06 メラノコルチン４受容体経路関連障害を治療する方法
JP2022155051A JP2022173426A (ja) 2015-09-30 2022-09-28 メラノコルチン４受容体経路関連障害を治療する方法
JP2024204921A JP2025019234A (ja) 2015-09-30 2024-11-25 メラノコルチン４受容体経路関連障害を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235003P 2015-09-30 2015-09-30
US62/235,003 2015-09-30
PCT/US2016/054457 WO2017059076A1 (en) 2015-09-30 2016-09-29 Method of treating melanocortin-4 receptor pathway-associated disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021064764A Division JP7752373B2 (ja) 2015-09-30 2021-04-06 メラノコルチン４受容体経路関連障害を治療する方法

Publications (3)

Publication Number Publication Date
JP2018531937A JP2018531937A (ja) 2018-11-01
JP2018531937A5 true JP2018531937A5 (https=) 2019-11-07
JP6940853B2 JP6940853B2 (ja) 2021-09-29

Family

ID=57138146

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2018517270A Active JP6940853B2 (ja) 2015-09-30 2016-09-29 メラノコルチン４受容体経路関連障害を治療する方法
JP2018517274A Active JP7051106B2 (ja) 2015-09-30 2016-09-29 メラノコルチン－４受容体経路関連障害の治療方法
JP2021041611A Pending JP2021088611A (ja) 2015-09-30 2021-03-15 メラノコルチン−４受容体経路関連障害の治療方法
JP2021064764A Active JP7752373B2 (ja) 2015-09-30 2021-04-06 メラノコルチン４受容体経路関連障害を治療する方法
JP2022155051A Pending JP2022173426A (ja) 2015-09-30 2022-09-28 メラノコルチン４受容体経路関連障害を治療する方法
JP2023044399A Withdrawn JP2023078335A (ja) 2015-09-30 2023-03-20 メラノコルチン－４受容体経路関連障害の治療方法
JP2024204921A Pending JP2025019234A (ja) 2015-09-30 2024-11-25 メラノコルチン４受容体経路関連障害を治療する方法
JP2026000058A Pending JP2026042856A (ja) 2015-09-30 2026-01-04 メラノコルチン－４受容体経路関連障害の治療方法

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2018517274A Active JP7051106B2 (ja) 2015-09-30 2016-09-29 メラノコルチン－４受容体経路関連障害の治療方法
JP2021041611A Pending JP2021088611A (ja) 2015-09-30 2021-03-15 メラノコルチン−４受容体経路関連障害の治療方法
JP2021064764A Active JP7752373B2 (ja) 2015-09-30 2021-04-06 メラノコルチン４受容体経路関連障害を治療する方法
JP2022155051A Pending JP2022173426A (ja) 2015-09-30 2022-09-28 メラノコルチン４受容体経路関連障害を治療する方法
JP2023044399A Withdrawn JP2023078335A (ja) 2015-09-30 2023-03-20 メラノコルチン－４受容体経路関連障害の治療方法
JP2024204921A Pending JP2025019234A (ja) 2015-09-30 2024-11-25 メラノコルチン４受容体経路関連障害を治療する方法
JP2026000058A Pending JP2026042856A (ja) 2015-09-30 2026-01-04 メラノコルチン－４受容体経路関連障害の治療方法

Country Status (20)

Country Link
US (5) US20180215790A1 (https=)
EP (5) EP4360704A3 (https=)
JP (8) JP6940853B2 (https=)
KR (1) KR20180063221A (https=)
CN (2) CN108431023B (https=)
AU (6) AU2016330773A1 (https=)
BR (1) BR112018006674A2 (https=)
CA (2) CA3000673A1 (https=)
DK (1) DK3356386T3 (https=)
ES (1) ES2985734T3 (https=)
FI (1) FI3356386T3 (https=)
HK (1) HK1259424A1 (https=)
IL (3) IL299541A (https=)
MA (2) MA43040A (https=)
MX (2) MX2018003983A (https=)
PL (1) PL3356386T3 (https=)
PT (1) PT3356386T (https=)
SG (1) SG10202101510XA (https=)
WO (2) WO2017059076A1 (https=)
ZA (1) ZA201802704B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862444A1 (en) 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
MA43040A (fr) * 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4
BR112020009648A2 (pt) * 2017-11-15 2020-11-10 Rhythm Pharmaceuticals, Inc. formulações peptídicas de liberação prolongada
CA3090966A1 (en) 2018-02-20 2019-08-29 Charite - Universitatsmedizin Berlin Mc4r agonist efficacy in subjects with mc4r deficiencies and impaired nfat signaling
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
CN108841932B (zh) * 2018-07-13 2021-03-12 东北农业大学 一种预示和鉴定鸡腹部脂肪量的分子标记方法及应用
WO2021225972A1 (en) * 2020-05-04 2021-11-11 Regeneron Pharmaceuticals, Inc. Proprotein convertase subtilisin/kexin type 1 (pcsk1) variants and uses thereof
EP4216979A4 (en) * 2020-09-24 2024-11-06 Rhythm Pharmaceuticals, Inc. Methods of treating melanocortin-4 receptor pathway-associated disorders
JP2024532294A (ja) * 2021-08-24 2024-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｃ４ｒアゴニストペプチド
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
EP4618952A2 (en) * 2022-11-18 2025-09-24 Rhythm Pharmaceuticals, Inc. Methods for treating obesity with an mc4r agonist
WO2024155828A1 (en) * 2023-01-18 2024-07-25 Loma Linda University Health Uses of aminopyridines in the management of weight and satiety
CN118530299B (zh) * 2023-08-25 2025-02-07 广州益养生物科技有限公司 一种三肽、三肽盐或衍生物及其应用
WO2026022136A1 (en) * 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5226895A (en) 1989-06-05 1993-07-13 Eli Lilly And Company Multiple dose injection pen
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU1860697A (en) 1995-09-08 1997-07-28 Visionary Medical Products Corporation Pen-type injector drive mechanism
US5688251A (en) 1995-09-19 1997-11-18 Becton Dickinson And Company Cartridge loading and priming mechanism for a pen injector
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US20030144174A1 (en) 1998-12-09 2003-07-31 Miles B. Brennan Methods for identifying compounds useful for the regulation of body weight and associated conditions
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
DE10251673A1 (de) 2001-11-09 2003-07-10 Hoffmann La Roche Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms
US20060147936A1 (en) 2003-02-19 2006-07-06 Ulrich Frey Use of a gene mutation in the human gnas gene for predicting risks of diseases, courses of the disease and for predicting the response to disease therapies
GB0304822D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
EP1617832B1 (en) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
CA2530024A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
PL2286825T3 (pl) 2005-07-08 2017-06-30 Ipsen Pharma Ligandy receptora melanokortyny
JP2009500426A (ja) 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
US8247530B2 (en) 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
EP2106405A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2008087187A1 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
JP2010516654A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
WO2008087188A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
ES2618315T3 (es) 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
TW201002340A (en) 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
JP5530438B2 (ja) 2008-08-06 2014-06-25 ファイザー・リミテッド Ｍｃ４作動薬としてのジアゼピンおよびジアゾカン化合物
US8563742B2 (en) 2008-08-29 2013-10-22 High Point Pharmaceuticals, Llc Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
EP2168965A1 (en) 2008-09-25 2010-03-31 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists
WO2010037081A1 (en) 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
FR2937973B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2937868B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
JP2012509862A (ja) 2008-11-25 2012-04-26 ノヴォ・ノルディスク・アー／エス 肥満の治療のためのペプチド
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
WO2010065800A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Hydrazine substituted piperidine melanocortin receptor-specific compounds
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
EP2210885A1 (en) 2009-01-14 2010-07-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
WO2010096854A1 (en) 2009-02-27 2010-09-02 Mimetica Pty Ltd Methods of modulating the activity of the mc3 and/or mc4 receptors and treatment of conditions related to these receptors
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
KR101726893B1 (ko) * 2009-06-08 2017-04-13 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
BR112012002445A2 (pt) 2009-08-05 2015-10-13 Ipsen Pharma Sas uso de um agonista do receptor 4 de melanocortina.
CN102574894A (zh) 2009-08-31 2012-07-11 张力控制股份有限公司 稳定化的黑皮质素配体
US9314509B2 (en) 2009-11-16 2016-04-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
CA2862444A1 (en) * 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
PL2970389T3 (pl) 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
MA43040A (fr) 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4

Similar Documents

Publication Publication Date Title
JP2018531937A5 (https=)
JP2021102650A5 (https=)
US12263202B2 (en) Method of treating melanocortin-4 receptor pathway-associated disorders
Paran et al. Octreotide treatment in patients with severe acute pancreatitis
AU2025213562A1 (en) Pharmaceutical compositions
Page Immunologic effects of opioids in the presence or absence of pain
JP2006515351A5 (https=)
US11702448B2 (en) Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
Gibbons et al. Involvement of brain opioid receptors in the anti-allodynic effect of hyperbaric oxygen in rats with sciatic nerve crush-induced neuropathic pain
Kim et al. Two novel insulin receptor gene mutations in a patient with Rabson-Mendenhall syndrome: the first Korean case confirmed by biochemical, and molecular evidence
CN110237239A (zh) 用于治疗肥胖和体重管理的glp-1组合物
JP2005511563A (ja) チモシンα１ペプチドを投与する方法
Kim et al. Potential of a novel long-acting glucagon analog, HM15136, for the treatment of obesity
JP7242059B2 (ja) シェーグレン症候群の治療用ペプチド
Tombal et al. Optimal testosterone control and Eligard®
HK40077660A (en) Melanocortin-4 receptor agonists for the treatment of disorders characterised by pomc gene hypermethylation
HK40073416A (en) Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
RU2785889C1 (ru) Способ лечения нарушений, ассоциированных с путем рецептора меланокортина 4
Taylor et al. # 135 Long-term neuro-endocrine-immune effects of traumatic brain injury
Takahashi et al. Insulin-like Growth Factor I (IGF-I) Therapy in a Patient with Severe Insulin Resistance Syndrome
Page Analgesia administration attenuates surgery-induced tumor promotion
Pankov Genetic variations in the regulation of energy balance
Schyogolev et al. Synthetic somatostatin analogues in cures of bleeding from esophageal varices
Holzenberger PL8 IGF-1 receptor in adults: What the cell-specific knockouts tell us
Sachatello The Effect of Pentobarbital on Exocrine Pancreatic Secretion with a Review of the Literature on the Effects of Barbiturates on Gastrointestinal Secretions in General